The authors noted that both primary options for treatment are currently being debated as to their efficacy and safety.
Despite a longer procedural time, laparoscopic myomectomy achieves superior results compared to open myomectomy when treating uterine fibroids, according to a literature search and meta-analysis in the journal Laparoscopic, Endoscopic and Robotic Surgery.1
The authors noted that both primary options for treatment are currently being debated as to their efficacy and safety.
A total of 10 randomized control trials published between 1996 and 2019 were selected by conducting a comprehensive literature search of PubMed, ScienceDirect, and the Cochrane Library, representing 449 patients who underwent laparoscopic myomectomy and 449 patients who underwent open myomectomy.
Compared to open myomectomy, laparoscopic myomectomy was linked to reduced blood loss (mean difference [MD] = -34.43; 95% confidence interval [CI]: -34.92 to -33.94 (P < 0.001), an attenuated decline in hemoglobin (MD = -1.04; 95% CI: -1.14 to -0.93 (P < 0.001), less postoperative pain at 24 hours (MD = -0.51; 95% CI:
-0.83 to -0.19 (P = 0.002), and fewer overall complications (odds ratio [OR] = 0.42; 95% CI: 0.24 to 0.71 (P = 0.001).
However, laparoscopic myomectomy had a longer operative time (MD = 12.96; 95% CI: 9.94 to 15.97 (P < 0.001).
But there were no significant differences in pregnancy rate (OR = 1.39; 95% CI: 0.72 to 2.68; P = 0.33) or recurrence rate of postoperative uterine fibroids (OR = 1.15; 95% CI: 0.60 to 2.18; P = 0.67) between the 2 groups.
The longer surgical time for laparoscopic myomectomy might be due to a steeper learning curve, according to the authors, who noted that the laparoscopic procedure requires high accuracy and concentration to enucleate, morcellate, and suture. A greater number and larger size myomas can also increase surgery time.
On the other hand, blood loss and hemoglobin reduction were less pronounced in laparoscopic myomectomy than in open myomectomy, due to the laparoscopic procedure’s ability to coagulate.
Bipolar diathermy was also preferred over monopolar because only the large vessels were targeted, thus inducing less destruction of healthy myometrium.
“The injection of antidiuretic hormone (vasopressin derivatives) or diluted adrenalin around the fibroid wall (extracapsular) causes blood vessels to constrict and minimizes the bleeding to facilitate dissection,” wrote the authors.
Likewise, temporary bilateral uterine artery clipping decreases the blood supply and bleeding during myoma excision versus open myomectomy.
Hence, the authors believe it is critical that surgeons prepare for transfusion with the laparotomic procedure.
Postoperative pain, which was measured via the visual analogue scale (VAS), was less with laparoscopy for wound healing. Surgical wound pain gauged by VAS is directly linked to the surgical duration and postoperative removal of CO2. Parity and the degree of abdominal wall laxity are also probably 2 important considerations that influence postop pain types.
Another drawback of open myomectomy is that organ damage to the peritoneal wall can precipitate an increase in inflammatory factors, which could result in a higher likelihood of febrile conditions.
Although the study found laparoscopic myomectomy preferable to open myomectomy, the results were dependent on patient selection by the gynecologist’s knowledge, as well as learning curve, equipment fidelity, instrument reliability, and hospital directives.
__
Reference
Laparoscopic RFA linked to enhanced pregnancy outcomes in uterine fibroid patients
May 18th 2024A recent study presented at the 2024 ACOG Clinical and Scientific Meeting reveals that laparoscopic radiofrequency ablation significantly improves pregnancy outcomes for women with uterine leiomyomas.
Read More
Pap Talk S4E4: RFA and uterine fibroids with Dr. Jessica Shepherd
March 30th 2022In this episode of Pap Talk, Jessica Shepherd, MD, MBA, FACOG, deep dives into the benefits of utilizing radio frequency ablation (RFA) for treatment of uterine fibroids, available RFA devices, and disparities in the condition.
Listen
Study finds antihypertensive treatment reduces uterine fibroids risk
April 23rd 2024A recent study revealed that patients with untreated or new-onset hypertension face elevated chances of uterine fibroid diagnosis, underscoring the potential of antihypertensive therapy in mitigating this risk among midlife individuals.
Read More
Physician-patient collaboration for uterine fibroid treatment options
May 12th 2021Contemporary OB/GYN®’s senior editor Angie DeRosa sat down with Ayman Al-Hendy, MD, and Sateria Venable of The Fibroid Foundation, to discuss the role of patient-physician collaboration in uterine fibroid treatment and management options.
Listen
Maternal history linked to uterine fibroid risk in Black women
April 11th 2024Delve into the findings of a recent study revealing the heightened risk of developing uterine fibroids among Black women with a maternal history of the condition, shedding light on crucial implications for patient care and advocacy.
Read More
Study finds relugolix-CT Improves HMB in Black women
February 19th 2024Recent research highlights the efficacy and safety of relugolix combination therapy in managing uterine fibroid-associated heavy menstrual bleeding specifically among Black women, demonstrating outcomes comparable to the broader population.
Read More